Fresenius
More legal trouble for Fresenius
FDA hits Fresenius with 3rd warning letter this year
Medicare’s proposed dialysis cut takes a toll on device makers
Updated July 2, 2013, at 3:45 p.m. with comment from NxStage Medical.
Updated July 2, 2013, at 5 p.m. with comment from Fresenius.
Dialysis technology makers slid hard today after the Center for Medicare & Medicaid Services proposed a reimbursement decrease of more than 9% for 2014.
Can a smartphone help spot a stroke? | MassDevice.com On Call
MASSDEVICE ON CALL — The app market is now home to the Spot a Stroke F.A.S.T. app, launched by the American Stroke Assn, the American Heart Assn. and the Ad Council.
The app, inspired by Australia’s Think F.A.S.T. stroke identification app, uses the acronym to simplify the steps a user can take to determine whether someone is having a stroke. The app provides information on symptoms, suggests steps the user can take to help identify a stroke and helps find nearby hospitals and connect with emergency services.
Fresenius reveals FDA warning letter
Fresenius (NYSE:FMS) said today that an FDA warning letter sent to its North American division isn’t likely to have an impact on its sales and earnings guidance for this year.
The German dialysis giant said the U.S. watchdog agency warned it about problems with its design verification and validation procedures at a plant in Ogden, Utah.
Lawsuits accuse Fresenius of concealing on GranuFlo, NaturaLyte risks
A spate of lawsuits accuse Fresenius Medical (NYSE:FMS) of deliberately concealing potentially fatal problems with a pair of since-recalled products used during dialysis.
DOJ drops Medicare fraud case against Fresenius
The U.S. Department of Justice dropped a lawsuit against Fresenius Medical (NYSE:FMS), which was accused of overcharging Medicare for kidney dialysis services.